SomnoMed (ASX:SOM) has published its Appendix 4C cash flow report for the quarter ending September 30, 2024. The company reported a net cash inflow from operating activities of $1,121,000 and ended the quarter with $16,404,000 in cash balances.
SomnoMed's latest quarterly cash flow report highlights a stable financial position, with a net cash inflow from operations and continued investments in property, plant, and intellectual property. The company started the quarter with $16,179,000 and closed it with $16,404,000 in cash and equivalents. Key operating activities included customer receipts of $25,366,000 and expenditures for manufacturing, staff, and corporate costs. The investing activities saw a net cash outflow of $722,000, while financing activities resulted in a $69,000 outflow. With no unused financing facilities and positive operating cash flows, SomnoMed continues to focus on sustaining its cash position and strategic investments.
The quarterly cash flow report reflects our strong operational performance and effective cash management strategies. We remain focused on maintaining our cash position while continuing investments in key areas to drive growth.